N/A
N=386
Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.
Alzheimer's Disease · Mild Cognitive Impairment
Bottom Line
View on ClinicalTrials.gov: NCT02309723 ↗Enrolled (actual)
386
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcome: Primary: Influence of the Neuroimaging Test on a Finding of Alzheimer's Disease as the Underlying Cause of the Mild Memory Loss — 3; 12; 9; 31 participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Beta amyloid imaging (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Tufts Medical Center
- Primary completion
- Sep 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Influence of the Neuroimaging Test on a Finding of Alzheimer's Disease as the Underlying Cause of the Mild Memory Loss |
3; 12; 9; 31; 34; 30 | — |
| PRIMARY Likelihood of Recommending a Medication Indicated for Alzheimer's Disease |
93; 76; 92 | — |
| PRIMARY Likelihood of Recommending That Spouse Take Various Cognitive Deficit Disease Management Measures |
67; 61; 66 | — |
Summary
When older patients develop cognitive problems - like memory loss - there may be any of several underlying causes, sometimes occurring in combination. Clinicians have a better chance of providing appropriate treatment if they understand what the cause of the problem is. A diagnostic tool can help the patient by helping the clinician to make a more accurate diagnosis. This study investigates whether a new diagnostic tool - beta amyloid imaging - may potentially improve medical practice. The tool can potentially improve practice only if it can influence clinical judgment. This study investigates whether the provision of beta amyloid imaging information influences clinical judgment. The investigators will conduct a survey that presents clinicians with descriptions of hypothetical older patients with cognitive complaints. Some of the respondents also receive beta amyloid imaging information. The investigators will test the investigators hypothesis that the information will affect diagnostic judgment and management recommendations by comparing the responses of clinicians who receive the beta amyloid information to the responses of clinicians who do not.
Eligibility Criteria
Inclusion Criteria
- Practicing clinicians describing their training and practice as any of the following: neurologist, geriatrician, psychiatrist.
- Included respondents must also attest that they are a physician who is experienced in the assessment and diagnosis of dementia.
Data sourced from ClinicalTrials.gov (NCT02309723). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.